Caricamento...
Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma
BACKGROUND: Patients with sarcomatoid renal cell carcinomas (sRCC) have poor outcomes and limited treatment options. Pre-clinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase II trial to evaluate the effic...
Salvato in:
| Pubblicato in: | Clin Genitourin Cancer |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5809227/ https://ncbi.nlm.nih.gov/pubmed/28870517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.028 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|